ENTITY
Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine (600276 CH)

403
Analysis
Health Care • China
Jiangsu Hengrui Medicine Co., Ltd. develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company's products include anti-tumor medicines, pain-killers, anti-infection medicines, aluminum foil, and other related products.
more
bullish•Kweichow Moutai
•16 Sep 2019 11:38

Shanghai/​​Shenzhen Connect Ideas: Pre-Mid Autumn Hard Liquor Outflows (2019-09-13)

In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...

Logo
454 Views
Share
bearish•MSCI World Index
•24 Aug 2019 06:23

Global Equity Strategy: Bearish-Leaning Developments Continue; Europe/UK Holding Above Support.

We remain cautious as the number of bearish-leaning developments continue to pile up. As a result we continue to believe global equities are...

Logo
478 Views
Share
•21 Aug 2019 02:46

Shanghai Henlius Biotech IPO Initiation: Going Large

Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...

Logo
846 Views
Share
•19 Jul 2019 11:28

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million.  In this insight, we...

Logo
904 Views
Share
•26 Jun 2019 10:29

China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)

BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...

Logo
552 Views
Share
x